BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy [Seeking Alpha]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Attruby posted $362m in 2025 sales but faces stiff competition from Pfizer and Alnylam, with future generic threats and no 2026 revenue guidance provided. BBIO reported a 2025 net loss of $725m on $502m revenue, highlighting ongoing high R&D and SG&A spending as it invests in pipeline expansion. Pipeline catalysts, including BBP-418 for LGMD2I/R9 and two additional NDA submissions in 2026, underpin the current valuation and potential future upside. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Evgeny Gromov/iStock via Getty Images Investment Overview In February last year, I downgraded the stock of BridgeBio Pharma, Inc. ( BBIO ) from Buy to Hold in a note for Seeking Alpha . As it turned out, this was a bad More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understandin
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma (BBIO) was upgraded by Royal Bank Of Canada to "moderate buy".MarketBeat
- Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Strength And Late Stage Pipeline Focus [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (BBIO) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $100.00 price target on the stock.MarketBeat
- Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here's Why [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 4/16/26 - Form SCHEDULE
- 4/13/26 - Form 4
- 4/9/26 - Form 144
- BBIO's page on the SEC website